Taking people in DenmarkPhase 1
Testing BBO-8520 in adults with advanced KRAS G12C lung cancer
Tests the drug BBO-8520 in adults with advanced lung cancer carrying a KRAS G12C mutation.
Key facts
- Who runs it
- Theras Inc.
- Where
- Copenhagen Oe, DenmarkSee the siteAlso in 1 other country, 8 sites
- Trial code
- Registry title
- A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 45 people, planned
- Started
- 10 Apr 2026
- Expected to end
- 7 May 2030
- Type of study
- Interventional
- Record updated
- 24 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer that has a KRAS G12C mutation. It tests the safety and effect of the drug BBO-8520.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced non-small cell lung cancer.
- Biomarker or test result
- The cancer must have a KRAS G12C mutation.
Where in Denmark
Also in 1 other country, 8 sites
- RigshospitaletCopenhagen Oe, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing BBO-8520 in adults with advanced KRAS G12C lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 24 September 2026